Opstapelen schreef op 3 mei 2021 08:35:
Stukje uit de R&D update voordat Ridder weer eens iets roept wat niet helemaal strookt met de feiten maar wel met zijn alternatieve waarheid.
PathFlow® SARS-CoV-2 IgG is a professional use LFT for the detection of SARS-CoV-2
IgG antibodies, launched as a CE-IVD on 31 March 2021. The test provides a rapid
turnaround time of results from ten minutes and has demonstrated sensitivity of 98% and
specificity of 99% in validation studies.
PathFlow® SARS-CoV-2 SMART IgG is a next generation LFT to detect and, importantly,
differentiate between IgG antibodies. The test is expected to assist clinicians in
understanding the impact of immunisation programmes, as well as the levels of immunity
derived from infection by the virus. The Company now expects to launch this test as a CEIVD in Q3 2021.
PathFlow® SARS-CoV-2 Antigen is a professional and home use LFT for the detection
of SARS-CoV-2 antigens using non-invasive anterior nasal swab samples to provide a
result in approximately 15 minutes. Novacyt has been working with a partner to develop
this test, which is able to detect the virus regardless of current known mutations. The
Company intends to launch the test as CE-IVD before the end of Q2 2021 and expects it
to complement Novacyt’s established position in COVID-19 PCR testing. As the market for
COVID-19 testing continues to develop, the Directors believe this product could add
significant revenues for Novacyt.